Keros Therapeutics, Inc. has announced that its board of directors has approved a new stock repurchase program. Under this authorization, the company may repurchase up to $5 million of its common stock.
The decision to initiate the program was made following the receipt of a $20 million development milestone payment. This payment was received under the license agreement with Takeda Pharmaceuticals U.S.A., Inc., specifically related to the elritercept program following the dosing of the first patient in the ELRiSE MF clinical trial.
Management has been granted the authority to repurchase outstanding shares through open market transactions and other methods permitted by applicable securities laws. The company noted that the timing and amount of any repurchases will be determined by factors such as market conditions, stock price, and contractual limitations. The program may be modified, suspended, or discontinued at any time without obligation to purchase a specific dollar amount or number of shares.
As of September 30, 2026, Keros reported cash and cash equivalents of $259.5 million. The company stated that, based on its current operating plans and after accounting for the milestone payment and the repurchase program, its cash position will be sufficient to fund operating expenses and capital expenditures into 2029.